Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Ribupatide phase 2 (obesity + PMOS)

Ribupatide phase 2 (obesity + PMOS)

Ribupatide (HRS9531) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ribupatide (HRS9531)
Population
obesity
Phase
2
Participants
158
Duration
32 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
ribupatide 4 mgobesity china32158—−20.2 % vs −2.6 %
Δ −17.6 pp
—0.0 vs 0.0———0.0 vs 0.0—verified
ribupatide 2 mgobesity china32158—−15.1 % vs −2.6 %
Δ −12.5 pp
—0.0 vs 0.0———0.0 vs 0.0—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (6)
  • ribupatide 4 mg · weight_tp · Results
    the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
  • ribupatide 4 mg · ae_dc · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • ribupatide 4 mg · sae · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • ribupatide 2 mg · weight_tp · Results
    the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
  • ribupatide 2 mg · ae_dc · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • ribupatide 2 mg · sae · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Ribupatide phase 2 (obesity + PMOS). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.